

Product Description

Pioneering GTPase and Oncogene Product Development since 2010

KCNN1 RABBIT PAB

货号: S222286

产品全名: KCNN1 兔多抗

基因符号 SK1; hSK1; SKCA1; KCa2.1

UNIPROT ID: Q92952 (Gene Accession - NP_002239)

背景: Action potentials in vertebrate neurons are followed by an afterhyperpolarization (AHP) that may persist for several seconds and may have profound consequences for the firing pattern of the neuron. Each component of the AHP is kinetically distinct and is mediated by different calcium-activated potassium channels. The protein encoded by this gene is activated before membrane hyperpolarization and is thought to regulate neuronal excitability by contributing to the slow component of synaptic AHP. The encoded protein is an integral membrane protein that forms a voltage-independent calcium-activated channel with three other calmodulin-binding subunits. This gene is a member of the KCNN family of potassium channel genes.

抗原: Synthetic peptide of human KCNN1

经过测试的应用: ELISA, IHC

推荐稀释比: IHC: 50-300; ELISA: 5000-10000

种属反应性: Rabbit


克隆性: Rabbit Polyclonal

亚型: Immunogen-specific rabbit IgG 纯化: Antigen affinity purification 种属反应性: Human, Mouse, Rat


成分: PBS (without Mg2+ and Ca2+), pH 7.4, 150 mM NaCl, 0.05% Sodium Azide and 40% glycerol

研究领域: Signal Transduction


储存和运输: Store at -20°C. Avoid repeated freezing and thawing




Immunohistochemistry analysis of paraffin embedded Human liver cancer tissue using 222286(KCNNI Antibody) at a dilution of 1/55(Cytoplasm).



In comparision with the IHC on the left, the same paraffin-embedded Human liver cancer tissue is first treated with the synthetic peptide and then with 222286(Anti-KCNN1 Antibody) at dilution 1/55.



The image on the left is immunohistochemistry of paraffinembedded Human cervical cancer tissue using 222286(Anti-KCNNI



In comparision with the IHC on the left, the same paraffin-embedded Human cervical cancer tissue is first treated with synthetic peptide



Product Description

Pioneering GTPase and Oncogene Product Development since 2010